Leukine

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com

Criteria Questions:

1. What is the patient's diagnosis?
   - ❑ Agranulocytosis (non-chemotherapy drug induced)
   - ❑ Stem cell transplantation-related indication
   - ❑ Myelodysplastic syndrome (anemia or neutropenia)
   - ❑ Acute myeloid leukemia
   - ❑ Neutropenia associated with HIV/AIDS
   - ❑ Aplastic anemia
   - ❑ Severe chronic neutropenia - Congenital neutropenia
   - ❑ Severe chronic neutropenia - Cyclic neutropenia
   - ❑ Severe chronic neutropenia - Idiopathic neutropenia
   - ❑ Hematopoietic syndrome of acute radiation syndrome
   - ❑ Neuroblastoma
   - ❑ Neutropenia (prevention or treatment) associated with myelosuppressive anti-cancer therapy
   - ❑ Other _____

2. What is the ICD-10 code? _____

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Hematopoietic Syndrome of Acute Radiation Syndrome

3. Will the requested medication be used for the treatment of radiation-induced myelosuppression following a radiological/nuclear incident? ❑ Yes ❑ No

Section B: Neuroblastoma

4. Is the patient's disease considered high-risk? ❑ Yes ❑ No

5. Will the requested medication be used in combination with ALL of the following medications? ❑ Yes ❑ No
   a) Dinutuxin (Unituxin)
   b) Interleukin-2 (aldesleukin) (Proleukin)
   c) isotretinoin (13-cis-retinoic acid)

6. Will the requested medication be used in combination with naxitamab-gqgk (Danyelza)?

Section C: Neutropenia (Prevention or Treatment) Associated with Myelosuppressive Anti-Cancer Therapy

7. Will the requested medication be used in combination with any other colony stimulating factor products within any chemotherapy cycle? ❑ Yes ❑ No

8. Will the patient be receiving chemotherapy and radiation therapy at the same time? ❑ Yes ❑ No

9. For which of the following indications is the requested medication being prescribed?
   - ❑ Primary prophylaxis of febrile neutropenia in a patient with a solid tumor or non-myeloid malignancy
   - ❑ Secondary prophylaxis of febrile neutropenia in a patient with a solid tumor or non-myeloid malignancy, *skip to #13*
   - ❑ Treatment of high risk febrile neutropenia, *skip to #15*
   - ❑ No

10. Has the patient received, is currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 20% or higher incidence of febrile neutropenia? ***ACTION REQUIRED: If Yes, please submit documentation confirming the patient's diagnosis and the chemotherapeutic regimen and no further questions.*** ❑ Yes ❑ No

11. Has the patient received, is currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 10-19% incidence of febrile neutropenia? ***ACTION REQUIRED: If Yes, please submit documentation confirming the patient's diagnosis and the chemotherapeutic regimen.*** ❑ Yes ❑ No

12. Is the patient considered to be at high risk for febrile neutropenia because of bone marrow compromise or co-morbidity, including any of the following? ***ACTION REQUIRED: If Yes, please submit documentation confirming the patient's risk factors. Indicate below and no further questions.***
    - ❑ Active infections, open wounds, or recent surgery
    - ❑ Age greater than or equal to 65 years
    - ❑ Bone marrow involvement by tumor producing cytopenias
    - ❑ Previous chemotherapy or radiation therapy
    - ❑ Poor nutritional status
    - ❑ Poor performance status

❑ Previous episodes of FN
❑ Other serious co-morbidities, including renal dysfunction, liver dysfunction, HIV infection, cardiovascular disease
❑ Persistent neutropenia
❑ Other bone marrow compromise or comorbidity not listed above _____
❑ None of the above

13. Has the patient experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of chemotherapy) from a prior cycle of similar chemotherapy?
❑ Yes ❑ No

14. For the planned chemotherapy cycle, will the patient receive the same dose and schedule of chemotherapy as the previous cycle (for which primary prophylaxis was not received)? ❑ Yes ❑ No *No further questions*

15. Does the patient have any of the following prognostic factors that are predictive of clinical deterioration?
❑ Age greater than 65 years
❑ Being hospitalized at the time of the development of fever
❑ Sepsis syndrome
❑ Invasive fungal infection
❑ Pneumonia or other clinically documented infection
❑ Prolonged (neutropenia expected to last greater than 10 days) or profound (absolute neutrophil count less than $0.1 \times 10^9/L$) neutropenia
❑ Prior episodes of febrile neutropenia
❑ None of the above

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com